SpectaCell, a new Ghent-based startup specialising in next-generation cell therapy analytics, has announced its official launch with €6 million in Seed funding. The company has spun out of imec, VIB and Ghent University.
The round was led by imec.xpand, with participation from PMV’s Flanders Future Tech Fund, InnovationQuarter Capital, Qbic and VIB.
Tony Montoye, CEO and co-founder of SpectaCell, said, “Breakthrough medicines need breakthrough tools. Researchers need to know much earlier which candidates deserve further investment and why. We are building a new standard in cell analysis: detailed insight, results within hours and a simple workflow that connects research with manufacturing.
“Together with our biopharma partners, we will turn that vision into a platform for developing better treatments more efficiently. And ultimately, that is what we want to make possible for patients: better medicines, sooner.”
Founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde and Tony Montoye, SpectaCell is a Belgian life sciences company developing a next-generation cell analysis platform for drug development and manufacturing.
Its proprietary technology combines digital imaging and data analysis to measure how treatments affect individual cells.
According to the company, immunotherapies are opening new ways to treat cancer and diseases of the immune system. Yet predicting which candidates will work in patients and producing them consistently remain major challenges. It notes that developers need a clearer view of what a treatment actually does, earlier in the process. Slow, fragmented testing can leave critical gaps in that understanding and delay decisions while patients wait.
SpectaCell claims to tackle these testing bottlenecks with a next-generation cell analysis platform that measures how treatments affect individual cells. Applications include cell therapies and T-cell engagers that help immune cells recognise and attack cancer cells.
“Developers of new immune therapies need to understand what happens when a treatment meets its target: does it kill a cancer cell, for example, and how do individual cells respond? Many existing tests provide only part of that picture because they measure indirect signals or averages across a sample. Important differences between cells can disappear in those averages,” the company mentioned in the press release.
SpectaCell highlighted that it combines chip-based imaging with data analysis to track large numbers of individual cells and their interactions directly, at high resolution and over time. The technology does not require fluorescent labels that can interfere with cell behaviour. The company is developing an easy-to-use, cartridge-based instrument designed to deliver these insights in hours rather than days.
It is targeting pharmaceutical and biotechnology companies and specialist manufacturers worldwide. The company is developing a single platform for use from early research and process development through to routine manufacturing quality checks. The Belgian company says it will enable researchers to compare drug candidates, development teams to improve production processes, and manufacturers to assess whether each batch meets required performance standards.
Benoit Devogelaere, Partner at imec.xpand, said, “SpectaCell brings together disruptive semiconductor technology, an experienced team and a major commercial opportunity in drug development and manufacturing.
“We are convinced that SpectaCell can become essential to how new medicines are selected, developed and produced. With applications across cell therapies, T-cell engagers and other advanced treatments, we see the potential to set a new industry standard and build a globally competitive life-sciences business. We are proud to lead this round and back that ambition.”
The company plans to use this capital to fund further development and commercialisation of the platform with pharmaceutical and biotechnology partners.